lung cancer non-small cell lung carcinoma
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Three groups of 10 evaluable patients, i.e. 30 evaluable patients, with histologically proven NSCLC, with an activating EGFR mutation as assessed by HRM and DNA-sequencing;- Three groups are:;1. Patients who were never treated with TKI, planned to receive TKI therapy. ;2. Patients who relapse under TKI therapy, planned to stop TKI therapy;3. Patients who relapsed after second line cytotoxic chemotherapy and are planned for TKI retreatment. ;- Age between 18 and 70 years;- Life expectancy of at least 12 weeks;- Malignant lesions (at least 2) of at least 1.5 cm diameter as measured by CT ;- Karnofsky index >
Exclusion criteria
Exclusion criteria: - Claustrophobia;- Pregnant or lactating patients;- Concurrent treatment with experimental drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor-to-blood ratio (TBR) measures of [11C]erlotinib uptake in tumors and metastases Correlation between TBR form different lesions and parts of tumor lesions | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of tumor TBR with EGFR mutational status Correlation of TBR in tumors and metastases with [18F]FDG standardized uptake values (SUV) Correlation of tumor TBR with radiologic changes under TKI therapy (using RECIST) | — |
Countries
Netherlands
Outcome results
None listed